XML 58 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Provision

A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:

 

   2024   2023 
Federal   21.00%   21.00%
State   2.07%   2.55%
Nondeductible expenses   -2.33%   -3.85%
Change in valuation allowance   -20.74%   -19.70%
Effective tax rate   -    - 
Schedule of Deferred Tax Assets

A summary of the Company’s deferred tax assets is as follows:

 

   2024   2023 
U.S Federal and State net operating loss  $3,083,545   $2,429,544 
Stock based compensation   1,272,925    1,031,860 
Accrued salaries   382,288    395,899 
Orphan drug credit   1,060,118    924,171 
Derivative liability   -    370,572 
Other   260,481    392,486 
Total net deferred tax assets   6,059,357    5,544,532 
Valuation allowance   (6,059,357)   (5,544,532)
Total Deferred Tax Asset  $-   $-